<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<?properties manuscript?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-journal-id">8912860</journal-id>
<journal-id journal-id-type="pubmed-jr-id">1403</journal-id>
<journal-id journal-id-type="nlm-ta">Am J Reprod Immunol</journal-id>
<journal-id journal-id-type="iso-abbrev">Am. J. Reprod. Immunol.</journal-id>
<journal-title-group>
<journal-title>American journal of reproductive immunology (New York, N.Y. : 1989)</journal-title>
</journal-title-group>
<issn pub-type="ppub">1046-7408</issn>
<issn pub-type="epub">1600-0897</issn>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">29243317</article-id>
<article-id pub-id-type="pmc">6051706</article-id>
<article-id pub-id-type="doi">10.1111/aji.12800</article-id>
<article-id pub-id-type="manuscript">NIHMS967291</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>IL-17 in Neonatal Health and Disease</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Lawrence</surname>
<given-names>Shelley M.</given-names>
</name>
<degrees>MD, MS</degrees>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Ruoss</surname>
<given-names>J. Lauren</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="A3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Wynn</surname>
<given-names>James L.</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="author-notes" rid="FN1">†</xref>
<xref ref-type="aff" rid="A3">3</xref>
<xref ref-type="aff" rid="A4">4</xref>
</contrib>
</contrib-group>
<aff id="A1">
<label>1</label>University of California, San Diego, College of Medicine, Department of Pediatrics, Division of Neonatal-Perinatal Medicine</aff>
<aff id="A2">
<label>2</label>University of California, San Diego, Department of Pediatrics, Division of Host-Microbe Systems and Therapeutics</aff>
<aff id="A3">
<label>3</label>University of Florida, College of Medicine, Department of Pediatrics, Division of Neonatal-Perinatal Medicine</aff>
<aff id="A4">
<label>4</label>University of Florida, Department of Pathology, Immunology, and Laboratory Medicine</aff>
<author-notes>
<corresp id="FN1"><label>†</label><bold>Corresponding Author:</bold> James L. Wynn, MD. Division of Perinatal-Neonatal Medicine, Department of Pediatrics, The University of Florida; 1600 SW Archer Rd, P.O. Box 100296, Gainesville, Florida 32610-0296; <email>james.wynn@peds.ufl.edu</email>. Phone: (352) 273-8985. Shelley M. Lawrence MD, MS. Division of Perinatal-Neonatal Medicine, Department of Pediatrics, The University of California, San Diego; 9500 Gilman Drive, MC0760, La Jolla, California 92093-0760; <email>slawrence@ucsd.edu</email>. Phone: (303) 704-8908; Fax: (858) 822-3593</corresp>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>17</day>
<month>5</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="epub">
<day>15</day>
<month>12</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="ppub">
<month>5</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>01</day>
<month>11</month>
<year>2018</year>
</pub-date>
<volume>79</volume>
<issue>5</issue>
<fpage>e12800</fpage>
<lpage>e12800</lpage>
<!--elocation-id from pubmed: 10.1111/aji.12800-->
<abstract>
<p id="P1">Over the last few years, scientific interest in the cytokine IL-17A has intensified as its role in human health and disease has been elucidated. Discovered almost a quarter century ago, IL-17A is known to have poor biologic activity when acting alone, but attains robust actions when working synergistically with potent mediators of proinflammatory immune responses, such as IL-6 and IL-8. IL-17A is produced by specialized innate immune cells that protect host barriers from the outside world. Like sentries, these innate immune cells can “sound the alarm” through increased production of IL-17A, causing activation and recruitment of primed neutrophils and monocytes when pathogens escape initial host defenses. In this way, IL-17A promulgates mechanisms responsible for pathogen death and clearance. However, when IL-17A pathways are triggered during fetal development, due to chorioamnionitis or <italic>in utero</italic> inflammatory conditions, IL-17A can instigate and/or exacerbate fetal inflammatory responses that increase neonatal morbidities and mortality associated with common neonatal conditions such as sepsis, bronchopulmonary dysplasia (BPD), patent ductus arteriosus (PDA), and necrotizing enterocolitis (NEC). This review details the ontogeny of IL-17A in the fetus and newborn, discusses how derangements in its production can lead to pathology, and describes known and evolving therapies that may attenuate IL-17A-mediated human conditions.</p>
</abstract>
<kwd-group>
<kwd>IL-17</kwd>
<kwd>neonate</kwd>
<kwd>sepsis</kwd>
<kwd>patent ductus arteriosus</kwd>
<kwd>necrotizing enterocolitis</kwd>
<kwd>bronchopulmonary dysplasia</kwd>
<kwd>retinopathy of prematurity</kwd>
</kwd-group>
</article-meta>
</front>
</article>
</pmc-articleset>